Abstract Wild-type sequence (wt) p53 peptides are attractive candidates for broadly applicable cancer vaccines. Evidence has been accumulating which indicates that CD4+ Th cells have an important role in generating and maintaining antitumor immune responses. To elucidate the nature of CD4+ Th responses to wt p53 epitopes in patients with squamous cell carcinoma of the head and neck (SCCHN), peripheral blood mononuclear cells (PBMCs) from HLA-DP5+ patients were stimulated with HLA-DP5-restricted wt p53 peptides, p53 108-122 or p53 [153][154][155][156][157][158][159][160][161][162][163][164][165][166] , and tested for the release of IFN-and IL-5 in ELISPOT assays. Immunohistochemistry for p53 accumulation in tumors, and ELISA for serum antibodies to p53 were also performed. Eleven (57.9%) of 19 HLA-DP5+ patients but none of 5 healthy donors had detectable Th1 and/or Th2 responses to wt p53 peptides by ELISPOT assay. Among these 11 responding patients, 9 (81.8%) and all 11 (100%) patients had a tumor burden and p53 accumulation, respectively. On the other hand, two responding patients were in post-operative condition. Interestingly, among nine patients with a tumor burden, four patients with early disease showed either Th1-polarized or mixed Th1/Th2 responses, while Wve patients with advanced disease showed either Th2-polarized or mixed Th1/Th2 responses. Our results suggest that wt p53 108-122 and p53 153-166 peptides stimulate both Th1-and Th2-type CD4+ T cell responses in patients with SCCHN, and anti-p53 Th responses may persist even after surgical resection of the tumor; however, the presence of a tumor and its progression may aVect the nature of immune responses to wt p53 peptides.
Introduction
The targeting of wild-type sequence (wt) p53 epitopes represents an attractive approach for developing cancer vaccines capable of targeting a wide range of human cancers. Current evidence indicates that CD4+ Th cells as well as CD8+ CTL are required for eVective antitumor immunity and that peptide-based vaccines are more eVective when they include tumor-speciWc Th cell-as well as CTL-deWned peptides [13, 25] . Recently, we have demonstrated the identiWcation of a naturally presented HLA-DRB1*0401-restricted wt p53 peptide, p53 [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] , and the ability of these CD4+ T cells to enhance the ex vivo generation and function of antitumor CD8+ T cell eVectors [4] . More recently, the presence of anti-wt p53 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] CD4+ Th cells was shown to enhance the in vitro generation/expansion of HLA-A2-restricted, anti-wt p53 264-272 CD8+ T cells, which from one donor were initially "nonresponsive" to the wt p53 [264] [265] [266] [267] [268] [269] [270] [271] [272] peptide [12] . These anti-wt p53 Th cells produced IFN-, but not IL-5, indicating Th1 cytokine proWles; thus, anti-p53 Th cells could be crucial participants in the development of CD8+ CTL responses, including anti-wt p53-speciWc CTLs. Polarization toward the Th1 immune response in cancer patients is favorable for antitumor immunity; however, it is highly likely that skewing toward a Th2 bias is a common feature of various malignant diseases and this imbalance seems to be associated with the development of cancer. Actually, Fedoseyeva et al. [8] demonstrated that wt p53 peptides induced MHC class II-restricted CD4+ T cell responses dominated by T cells displaying a Th2 phenotype, in BALB/c tumor-bearing mice. In humans, Bueter et al. [3] have also reported that the majority of p53 determinants that are immunogenic in colorectal cancer patients induce the activation of IL-10-producing T cells. In contrast, van der Burg et al. [23] have reported that several proliferative responses in colon cancer patients show a Th1 cytokine proWle. These data suggest that the pattern of antip53 Th responses in cancer patients might be regulated by various factors, including the amounts and nature of p53 epitopes, HLA class II allele, and host immune status.
p53 was originally identiWed as a transformation-related antigen by IgG antibodies present in the sera of mice immunized against chemically induced tumors [7] . Subsequently, anti-p53 IgG was detected in the sera of patients with various types of cancer [6, 20, 26] . The IgG nature of anti-p53 humoral responses in cancer patients mandates that anti-p53 responses involve CD4+ T cells and suggested that p53-speciWc CD4+ Th cells are induced in these individuals. Tilkin et al. [22] demonstrated that the T cells of breast cancer patients proliferated in response to wt p53 protein, and these p53-speciWc responses were only detected in patients displaying high p53-speciWc IgG titers, whereas van der Burg et al. [23] indicated that patients with colorectal cancer displayed anti-p53 T helper immunity in the absence of measurable p53-speciWc antibody levels. Similarly, Bueter et al. [3] reported that the presence of T helper immunity was not necessarily linked with a p53-speciWc IgG response. Thus, the relation between anti-p53 Th responses, including the type of Th1/Th2 responses and the presence of anti-p53 antibodies, remain unclear.
Better understanding of the nature and speciWcity of antip53 Th responses in cancer patients is necessary to better design and develop more eVective p53-based cancer vaccines. In the present study, we investigated CD4+ Th responses to HLA-DPB1*0501-restricted wt p53 epitopes in patients with squamous cell carcinoma of the head and neck (SCCHN). An HLA-DPB1*0501 is a dominant HLA class II allele expressed in 60% of Japanese and two wt p53-derived peptides, p53 108-122 and p53 [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] , are known to stimulate CD4+ T cell responses when presented in the context of the HLA-DPB1*0501 allele [9] ; therefore, we chose these two peptides in this study. Moreover, immunological response data were evaluated relative to the p53 status, the presence of anti-p53 antibodies, and the disease status in each subject with SCCHN.
Materials and methods

Subjects
Peripheral blood was obtained from 27 subjects with pathologically and clinically conWrmed SCCHN and 5 healthy subjects. The study was approved by the Institutional Review Board at Gunma University Hospital and written informed consent was obtained from each individual. Patient characteristics are summarized in Table 1 . Heparinized venous blood (40 mL) was obtained from all subjects, and peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation over Ficoll-Hypaque gradients (Amersham Biosciences, Uppsala, Sweden), washed, and counted in the presence of a trypan blue dye.
HLA-DPB1*0501 genotyping was performed using a commercial DP5 typing panel of PCR primers according to the manufacturer's instructions (Dynal, Oslo, Norway).
Cell line and peptide
The H0301 cell line, HLA-DPB1*0501 homozygous Epstein-Barr virus (EBV)-transformed B lymphocytes (EBV-B cells), used as the peptide-presenting cells in ELI-SPOT assays, was kindly provided by Dr. Nishimura (Kumamoto University, Kumamoto, Japan). It was maintained in RPMI 1640 (Sigma-Aldrich, St Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, 100 g/mL streptomycin, 2 mM L-glutamine (all reagents from Invitrogen, Grand Island, NY). HLA-DPB1*0501-restricted wt p53-derived peptides, p53 108-122 (GFRLGFLHSGTAKSV) and p53 [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] (PGTRVRAMAIYKQS) were synthesized using standard N-(9-Xuorenyl) methoxycarbonyl methodology. The peptide was stored as a lyophilized preparation. The amino acid sequence was conWrmed by mass spectrometric analysis.
In vitro sensitisation with peptides PBMCs were cultured in the presence of wt p53-derived peptide (10 g/ml) in 24-well tissue culture plates (Becton Dickinson Labware, Franklin Lakes, NJ) in a Wnal volume of 2 mL AIM-V medium (Invitrogen) containing 10% (v/v) human AB serum (DS Pharma Biomedical, Osaka, Japan) (complete medium: CM). After 3 days, half of the medium from each well was replaced with CM-containing peptide (10 g/ml). Following 4 days of incubation at 37°C, PBMCs were harvested, washed and tested in ELISPOT assays. In some cases, intracellular Xow cytometric analysis was also performed.
Flow cytometric analysis
Responder cells (1 £ 10 6 cells) were stimulated with 10 g/ mL peptides (wt p53 108-122 or p53 [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] ) in the presence of irradiated (30 Gy) PBMCs (1 £ 10 6 cells). After 1 h, 2 M monensin A (Sigma, St Louis, MO) were added. After an additional 5 h of incubation, responder cells were harvested, washed twice with PBS, and stained with allophycocyanin (APC)-conjugated anti-CD4 monoclonal antibody for 30 min at 4°C. After washing twice, the responder cells were Wxed and permeabilised according to the manufacturer's instructions (BD CytoWx/Cytoper™, Fixation/ Permeabilization Kit, BD Biosciences, San Jose, CA). The cells were stained with PE-conjugated anti-IFN-(BD Biosciences) for 30 min at 4°C. As a negative control, cells were stained with mouse IgG isotype control (BD Biosciences). Cells were washed twice, and then analyzed by Xow cytometry. Dead cells were eliminated using the viability dye 7-aminoactinomycine (7-AAD; BD Biosciences).
IFN-and IL-5 ELISPOT assays
ELISPOT assays were performed in 96-well Xat-bottomed plates with nitrocellulose membrane inserts (Millipore, Bedford, MA), as previously described [1, 4] . BrieXy, the plates were coated overnight at 4°C with 10 g/mL antihuman IFN-mAb (1-D1 K: Mabtech, Nacka Strand, Sweden), or 5 g/ml anti-human IL-5 mAb (TRFK5: BD Pharmingen, San Diego, CA) in PBS. H0301 cells used as APCs were pulsed with a wt p53 108-122 or p53 153-166 (10 g/ ml) and plated in triplicate wells at 1 £ 10 5 cells/well. Responder cells (1 £ 10 5 cells/well) were added to AIM-V medium at a Wnal volume of 200 l. PBMCs stimulated with 12.5 ng/ml PMA and 1 g/mL ionomycin were used as a positive control. The plates were incubated at 37°C for 20 h for IFN-assessment, and 40 h for IL-5 assessment. After incubation, the plates were washed with PBS/0.05% Tween 20, and supplemented with biotinylated anti-IFNmAb (7-B6-1: Mabtech) or biotinylated anti-IL-5 mAb (JES1-5A10: BD Pharmingen). After 2 h incubation, plates were washed with PBS/0.05% Tween 20, and developed with the avidin-peroxidase complex (Vectastain Elite kit; Vector) for 1 h. 3-amino-9-ethyl-carbozole (Sigma, St Louis, MO) was added and incubated for 5 min for the IFN-ELISPOT assay and the TMB substrate for peroxidase (3,3Ј,5,5Ј-tetramethylbenzidine; Vector Laboratories) was added and incubated for 10 min for the IL-5 ELISPOT assay. Spot numbers were automatically determined using a computer-assisted video image analyzer (Zeiss-Kontron, Jena, Germany). The mean number of spots in control wells (no peptide) was subtracted from the mean number of spots in experimental wells. A T cell response to a given wt p53 peptide was considered to be positive if at least 10 cells per 1 £ 10 5 responder cells secreted IFN-or IL-5. In these cases, Student's two-tailed t test was performed to determine whether there was a signiWcant diVerence between the number of cytokine-secreting T cells in peptide-stimulated and unstimulated wells, as described by Nagorsen et al. [16] .
Immunohistochemistry for p53 and detection of p53 antibody in SCCHN Immunohistochemical detection of p53 in tumor specimens was performed as previously described [19] . BrieXy, formalin-Wxed, paraYn-embedded tissue blocks were sectioned (2 m thick) and deparaYnized. The slides were autoclaved in 0.01 M citrate buVer for 15 min (w/v) for antigen retrieval. After washing, sections were incubated with 1% (w/v) bovine serum albumin (SigmaAldrich, St Louis, MO) and 5% (w/v) normal horse serum (IBL, Gunma, Japan) for 30 min and subsequently treated overnight with anti-p53 mAb (DO-7; DAKO Cytomation, Inc., Carpinteria, CA). Next, sections were incubated with biotinylated goat anti-mouse antibodies (DAKO, Copenhagen, Denmark). The avidin-biotin complex technique (Vectastain Elite Kit; Vector Inc., Burlingame, CA) was performed according to the manufacturer's instructions, and 3,3Ј-diaminobenzidine tetrahydrochloride (DAB; Wako, Osaka, Japan) was used for color development. Sections were counterstained with hematoxylin. To avoid a scoring bias, p53 expression was evaluated by two independent observers. Staining was scored as either positive (>10% of tumor cell nuclei were stained) or negative.
Ab to p53 in the patient's sera was detected by ELISA purchased from PharmaCell Immunotech Coulter (Miami, FL) using microtiter plates coated with recombinant human wt p53 protein.
Statistical analysis
Student's two-tailed t test and Fisher's exact probability test were used for statistical analysis of data. All p values <0.05 were considered signiWcant. Analyses were performed using Statcel2 (OMS Publishing, Tokorozawa, Japan).
Results
wt p53 peptide-speciWc IFN-and IL-5 production by PBMCs obtained from healthy donors
Two wt p53 peptides (p53 108-122 and p53 153-166 ) were tested for their ability to induce wt p53 peptide-speciWc Th responses. Separate cultures of PBMCs were set up with each peptide. Following 2£ IVS, responder cells were evaluated for peptide-speciWc CD4+ T cell responses in IFN-(Th1-type) and IL-5 (Th2-type) ELISPOT assays. We Wrst tested PBMCs from Wve healthy donors; however, none of the healthy donors showed IFN-and/or IL-5 production signiWcantly above the background for any of the two peptides in this protocol (data not shown).
wt p53 peptide-speciWc IFN-production by PBMCs obtained from patients with SCCHN PBMCs obtained from 27 patients with SCCHN (19 HLA-DP5+ and 8 HLA-DP5-patients) were used in these experiments. Data in Table 2 indicate that PBMCs obtained from 7 (36.8%) of 19 HLA-DP5+ patients speciWcally produced IFN-to either of these two peptides tested, and 4 (21.1%) and 3 (15.8%) yielded a response to wt p53 108-122 and wt p53 153-166 peptides, respectively. As expected, no PBMCs obtained from eight HLA-DP5-patients responded to wt p53 peptides. In order to conWrm the presence of IFN--secreting CD4+ T cells within the PBMCs tested, in some cases (SCCHN-10, 11, 12, 17, 19 ), intracellular IFN-Xow cytometric analysis was performed. As can be seen from the representative results shown in Fig. 1, both (Table 2) . Unexpectedly, PBMCs obtained from SCCHN-25, an HLA-DP5-patient, produced IL-5 in response to two wt p53 peptides tested, suggesting that these peptides may be naturally present in the context of multiple HLA class II molecules.
Correlation of Th responses to wt p53 peptides with disease status, p53 accumulation, and anti-p53 Ab
To evaluate the impact of the tumor burden, p53 accumulation, and the presence of anti-p53 Ab on anti-p53 Th responses, further analysis was performed in 19 HLA-DP5+ patients tested (Table 3) . Overall, 11 (57.9%) of 19 HLA-DP5+ patients had detectable Th1 and/or Th2 responses to wt p53 peptides by ELISPOT assay. These included 3/11 (27.3%) patients with only Th1 responses, 4/11 (36.4%) patients with only Th2 responses, and 4/11 (36.4%) with mixed Th1/Th2 responses. Among 11 patients with Th responses to wt p53 peptides, 9/11 (81.8%) and all 11 (100%) patients had a tumor burden and p53 accumulation, respectively. On the other hand, two patients with Th responses to wt p53 peptides were in a post-operative condition. Thus, anti-p53 Th responses were found more frequently in patients with a tumor burden (p = 0.022) or p53 accumulation (p < 0.001) than in those with NED or no p53 accumulation signiWcantly (Table 4) . Meanwhile, there was no relation between anti-p53 Th responses and the presence of anti-p53 Ab (p = 0.337). Interestingly, among 9 patients with a tumor burden, four patients with early disease (stage I and II) showed either Th1-polarized or mixed Th1/Th2 responses to wt p53 peptides, while Wve patients with advanced disease (stage III and IV) showed either Th2-polarized or mixed Th1/Th2 responses. Although these data derive from relatively few patients, they suggest that disease progression may shift toward a Th2 skewed immune status.
Discussion
The primary objective of this study was to determine whether CD4+ T cells speciWc to wt p53-derived peptides could be induced from PBMCs obtained from patients with SCCHN. To date, several HLA class II-restricted, CD4+ T cell-deWned wt p53 epitopes have been identiWed and potentially could be used in vaccines against malignancies [4, 9, 12, 17] . Among these epitopes, p53 108-122 and p53 [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] were deWned as HLA-DP5-restricted peptides [9] . In this study, we analyzed wt p53-speciWc Th immunity in more detail using these two wt p53-derived-peptides. Our results indicated that the two peptides tested were comparable and could induce IFN-production as well as IL-5, suggesting that they stimulate Th1 and Th2 precursors in a subset of patients. Moreover, CD4+ T cell responses were conWrmed by intracellular IFN-Xow cytometric analysis. In contrast, in Wve healthy donors, no signiWcant responses were detected, suggesting the absence of wt p53-speciWc T cell precursors in these individuals. PBMCs obtained from one HLA-DP5-patient were able to produce IL-5 in response to p53 108-122 and p53 [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] . The length of the HLA class II peptide and the ability of the peptide to bind in the groove of HLA molecules can result in the HLA class II peptide being a promiscuous binder; therefore, several epitopes derived from tumor antigens have been shown to elicit Th responses across multiple HLA class II alleles [5, 10, 14, 15] . Indeed, p53 108-122 has also been identiWed as an epitope presented by HLA-DRB1*0101 and -DRB1*0401 alleles [17] . Genetic alteration in p53 is perhaps the most frequently encountered genetic event associated with human cancer, and provides the basis for enhanced presentation by tumors of p53 proteins for immune recognition. In this study, 7 of 19 HLA-DP5+ patients tested had anti-p53 Ab in their sera, and this frequency of anti-p53 Ab is similar to the results from previous reports [6, 20, 26] . Moreover, six of these seven patients had p53 accumulation in their tumor, indicating a good correlation between the presence of anti-p53 Ab and p53 accumulation. As expected, all 11 patients with anti-p53 Th responses showed p53 accumulation in their tumor, suggesting that p53 accumulation may be an important component in the development of cellular response as well as humoral responses. Notably, anti-p53 Th responses [11, 27] ; thus, the detection of humoral and cellular immune responses to wt p53 epitopes is not necessarily linked. Several recent reports have demonstrated that cellular responses to p53 are associated with clinicopathologic parameters, including the accumulation of T cells at the tumor site, tumor diVerentiation, and disease stage [2, 24] . Our previous study showed that CD8+ T cell precursors responsive to wt p53 epitopes were detected in the circulation of most subjects with early disease relative to subjects with advanced disease who were largely in the nonresponder category [18] . Interestingly, in patients with a tumor burden, our data indicated that patients with early disease showed either Th1-polarized or mixed Th1/Th2 responses, while those with advanced disease had either Th2-polarized or Th1/Th2 responses. In tumor-bearing mice, Fedoseyeva et al. [8] showed an anti-p53 CD4+ T cell response biased toward the Th2 type during the course of tumorigenesis. Similarly, in patients with renal cell carcinoma, Tatsumi et al. [21] also demonstrated that Th1-type biased CD4+ T cell reactivity to EphA2 peptides could only be observed in a subset of stage I patients, and Th2-or T regulatory-type biased CD4+ T cell reactivity was almost always observed in stage IV patients. To clarify any potential disease-associated Th1/Th2 bias in response to wt p53 peptides in patients with SCCHN, more extensive studies will be required; however, our data and those of others suggest that tumor development may shift toward a Th2 skewed immune status and play facilitating roles in disease progression; therefore, vaccine strategies able to shift the balance toward Th1 polarization may be essential for more eVective immunotherapy in patients with advanced disease.
Taken together, our study demonstrates that wt p53 108-122 and p53 153-166 peptides stimulate both Th1 and Th2-type CD4+ T cell responses in patients with SCCHN, and that Th responses to wt p53 epitopes may persist even after surgical resection of a tumor. Moreover, the nature of immune responses to wt p53 peptides may be skewed toward Th2-type responses during tumor progression. The value of using Th-deWned epitopes for vaccination is that, in addition to augmenting CTLs, they could augment other elements of host defense, including non-MHC-restricted inXammatory cells and natural killer cells, which can also function in tumor eradication; however, inadequate performance of an anti-cancer vaccine may lead to tolerance and/ or tumor escape; therefore, it will be necessary to employ much more robust vaccination strategies, possibly combining strong Th1-polarizing adjuvants and diVerent therapeutic modalities. 
